Vanderbilt Ingram Cancer Center

Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.

Using bioinformatics approaches, Vanderbilt investigators have identified gene expression networks that are deregulated in mouse and human stomach cancers.

Curiosity is the spark that has always energized and illuminated Eric Shinohara’s life — curiosity about the natural world, about other people and about how to help those individuals.

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

The Nashville Sounds baseball team recently highlighted cancer care at Vanderbilt-Ingram Cancer Center (VICC) during a special “Cancer Awareness Night.”

Researchers at Vanderbilt University Medical Center (VUMC) have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have mutations in the tumor suppressor gene BRCA2.

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.